Skip to content

Clinical Characteristics and Inflammatory Mechanism Research of Cardiorenal Metabolic Syndrome in Patients with Primary Aldosteronism

Clinical Characteristics and Inflammatory Mechanism Research of Cardiorenal Metabolic Syndrome in Patients with Primary Aldosteronism

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117383
Enrollment
Unknown
Registered
2026-01-23
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism

Interventions

Patients with primary aldosteronism:NA
Patients with essential hypertension:NA

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Without the use of antihypertensive drugs, the blood pressure measured upon admission was >= 140/90 mmHg, or there was a previous diagnosis of hypertension. 2. Patients with ARR >= 2 who have undergone the original aldosterone test for diagnosis and have agreed to undergo AVS for further classification; patients with ARR = 2 but whose original aldosterone test has ruled out the diagnosis of PA. 3. Patients aged between 35 and 70 who underwent ABI monitoring;

Exclusion criteria

Exclusion criteria: 1. Other patients with secondary hypertension, including renal hypertension, renovascular hypertension, pheochromocytoma and Cushing's syndrome, etc. 2. Significant abnormalities in liver function or a history of the following liver diseases: AST or ALT levels higher than the upper limit of normal by twice or more, history of liver cirrhosis, hepatic encephalopathy, history of esophageal varices or portosystemic shunt. 3. Recently, there has been a severe infection, trauma or surgical condition, or there is a known concurrent malignant tumor disease. 4. Missing important data;

Design outcomes

Primary

MeasureTime frame
The incidence of CKM stage ?/? ;The systemic immune inflammation index;The systemic inflammatory response index;

Countries

China

Contacts

Public ContactZhencheng Yan

Army Medical Center of PLA

zhenchengyan@sina.com+86 23 6872 9687

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026